核糖體蛋白S6激酶1抗體別 名:70 kDa ribosomal protein S6 kinase 2; EC 2.7.11.1; KS6B2_HUMAN; p70 beta; p70 ribosomal S6 kinase beta; p70 S6K-beta; p70 S6KB; p70 S6Kbeta; p70(S6K) beta; p70-beta; p70-S6K 2; P70S

公司產品僅用于科研專業供應的抗體，是用于化學反應、分析化驗、研究實驗、教學實驗、化學配方使用的純凈化學品，價格實惠，多種規格供應，售后完善。
英文名稱: p70 S6 kinase beta

中文名稱: 核糖體蛋白S6激酶1抗體

規格：50ul、100ul、200ul
別    名:70 kDa ribosomal protein S6 kinase 2; EC 2.7.11.1; KS6B2_HUMAN; p70 beta; p70 ribosomal S6 kinase beta; p70 S6K-beta; p70 S6KB; p70 S6Kbeta; p70(S6K) beta; p70-beta; p70-S6K 2; P70S6K2; p70S6Kb; Ribosomal protein S6 kinase 70kDa, polypeptide 2; Ribosomal protein S6 kinase beta 2; Ribosomal protein S6 kinase beta-2; Rps6kb2; S6 kinase related kinase; S6 kinase-related kinase; S6K beta 2; S6K beta; S6K-beta; S6K-beta-2; S6K2; Serine/threonine protein kinase 14 beta; Serine/threonine-protein kinase 14B; SRK; STK14B.

研究領域:信號轉導  轉錄調節因子  激酶和磷酸酶

抗體來源:Rabbit

克隆類型:Polyclonal

交叉反應:Mouse, Rat,  (predicted: Human, )

產品應用:WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200 （石蠟切片需做抗原修復）

not yet tested in other applications.

optimal dilutions/concentrations should be determined by the end user.

理論分子量:57kDa

細胞定位:細胞核 細胞漿

性    狀:Liquid

濃    度:1mg/ml

免 疫 原:KLH conjugated synthetic peptide derived from human RPS6KB2: 281-380/525

亞    型:IgG

純化方法:affinity purified by Protein A

緩 沖 液:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

注意事項:This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

產品介紹:This gene encodes a member of the ribosomal S6 kinase family of serine/threonine kinases. The encoded protein responds to mTOR (mammalian target of rapamycin) signaling to promote protein synthesis, cell growth, and cell proliferation. Activity of this gene has been associated with human cancer. Alternatively spliced transcript variants have been observed. The use of alternative translation start sites results in isoforms with longer or shorter N-termini which may differ in their subcellular localizations. There are two pseudogenes for this gene on chromosome 17. [provided by RefSeq, Jan 2013].

Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression. Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and contributes to cell survival by repressing the pro-apoptotic function of BAD. Under conditions of nutrient depletion, the inactive form associates with the EIF3 translation initiation complex. Upon mitogenic stimulation, phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) leads to dissociation from the EIF3 complex and activation. The active form then phosphorylates and activates several substrates in the preinitiation complex, including the EIF2B complex and the cap-binding complex component EIF4B. Also controls translation initiation by phosphorylating a negative regulator of EIF4A, PDCD4, targeting it for ubiquitination and subsequent proteolysis. Promotes initiation of the pioneer round of protein synthesis by phosphorylating POLDIP3/SKAR. In response to IGF1, activates translation elongation by phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and thus activation of EEF2. Also plays a role in feedback regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition of mTORC2 and AKT1 signaling. Mediates cell survival by phosphorylating the pro-apoptotic protein BAD and suppressing its pro-apoptotic function. Phosphorylates mitochondrial URI1 leading to dissociation of a URI1-PPP1CC complex. The free mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at 'Thr-412', which is proposed to be a negative feedback mechanism for the RPS6KB1 anti-apoptotic function. Mediates TNF-alpha-induced insulin resistance by phosphorylating IRS1 at multiple serine residues, resulting in accelerated degradation of IRS1. In cells lacking functional TSC1-2 complex, constitutively phosphorylates and inhibits GSK3B. May be involved in cytoskeletal rearrangement through binding to neurabin.
抗體基本結構：

抗體制備過程：

1.材料與試劑

 a．提取的動物 Ig

 b．弗氏佐劑和弗氏不佐劑

 d．實驗動物 兔

 e．其它材料及試劑

2、選擇實驗活體。

3、進行動物免疫實驗。

4、試取血樣進行測試，查看免疫效果。

5、如果免疫成功，殺死實驗活體，采集全部血清。

6、純化出抗體。

7、鑒定抗體。胎牛血清（無菌采制）

免疫熒光技術的實驗步驟：

一、準備好試劑與儀器：

磷酸鹽緩沖鹽水、熒光標記的抗體溶液、緩沖甘油、搪瓷桶三只、有蓋搪瓷盒一只、熒光顯微鏡、玻片架、濾紙、37℃溫箱等。

二、實驗步驟

1.滴加0.01mol/L，pH7.4的PBS于待檢標本片上，十分鐘后棄去，使標本保持一定濕度。

2.滴加適當稀釋的熒光標記的抗體溶液，使其覆蓋標本，置于有蓋搪瓷盒內，保溫一定時間以三十分鐘為參考。

3.取出玻片，置玻片架上，先用0.01mol/L，pH7.4的PBS沖洗后，再按順序過0.01mol/L，pH7.4的PBS三缸浸泡，每缸三到五分鐘，并不停地搖晃振蕩。

4.取出玻片，用濾紙吸去多余水分，但不使標本干燥，加一滴緩沖甘油，以蓋玻片覆蓋。

5.立即用熒光顯微鏡觀察。觀察標本的特異性熒光強度。

抗體的定義：

抗體（antibody），（免疫球蛋白不僅僅只是抗體）是一種由漿細胞（效應B細胞）分泌，被免疫系統用來鑒別與中和外來物質如細菌、病毒等的大型Y形蛋白質，僅被發現存在于脊椎動物的血液等體液中，及其B細胞的細胞膜表面。抗體能識別特定外來物的一個特征，該外來目標被稱為抗原。

動物抗體功能分類：

①豬抗體：豬瘟抗體，豬藍耳抗體，豬圓環病毒抗體，豬偽狂犬抗體，豬細小病毒抗體，豬口蹄疫抗體，豬流感抗體等。

②禽抗體:小鵝瘟抗體，鴨肝抗體抗體，鴨漿膜炎抗體，抗體，新城疫抗體等

③牛抗體：牛口蹄疫抗體，奶牛乳房炎抗體，牛流行熱抗體，牛病毒性腹瀉抗體，牛出血性敗血癥抗體等

④羊抗體：羊痘抗體，羊口蹄疫抗體，羊小反芻獸疫抗體，羊快疫抗體，羊腸毒血癥抗體，羊猝疽抗體，羊黑疫抗體等。

⑤犬抗體：犬狂犬病抗體、犬瘟熱抗體、犬副流感抗體、犬腺病毒抗體與犬細小病毒病抗體，狐貉水貂的偽狂犬抗體、細小病毒抗體、乙腦抗體等。

抗體的結構：

抗體是具有4條多肽鏈的對稱結構，其中2條較長、相對分子量較大的相同的重鏈(H鏈)；2條較短、相對分子量較小的相同的輕鏈(L鏈)。鏈間由二硫鍵和非共價鍵聯結形成一個由4條多肽鏈構成的單體分子。輕鏈有κ和λ兩種，重鏈有μ、δ、γ、ε和α五種。 整個抗體分子可分為恒定區和可變區兩部分。在給定的物種中，不同抗體分子的恒定區都具有相同的或幾乎相同的氨基酸序列。可變區位于"Y"的兩臂末端。在可變區內有一小部分氨基酸殘基變化特別強烈，這些氨基酸的殘基組成和排列順序更易發生變異區域稱高變區。高變區位于分子表面，最多由17個氨基酸殘基構成，少則只有2 ～ 3個。高變區氨基酸序列決定了該抗體結合抗原抗原的特異性。一個抗體分子上的兩個抗原結合部位是相同的，位于兩臂末端稱抗原結合片段(antigen-binding fragment, Fab)。"Y"的柄部稱結晶片段(crystalline fragment,FC)，糖結合在FC 上。

公司出售的產品：